Interim Report Q1 – January – March, 2022 Redsense Medical AB (publ)
January – March 2022 · Net sales amounted to kSEK 3,127 (685), an increase by 356 percent. · Operating loss, EBIT amounted to kSEK 2,076 (3,150). · Result after tax amounted to kSEK -1,549 (-1,489). · Earnings per share was SEK -0.11(-0.11) before and after dilution. Significant events during the period · On March 14, Redsense Medical successfully participated in a virtual briefing about venous needle dislodgement (VND) for US congress together with multiple professional renal organizations and advocacy associations. · On March 15, Redsense Medical announced that